A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan

<div>Ame55 accumulated in cells and tissues. (a) Antibody contents of Ame55 and C225 in A431 xenograft tumor tissues, with purified proteins as controls for the second antibody. (b) Antibody contents of Ame55 and C225 in Lovo xenograft tumor tissues. (c) Content of EGFR, pEGFR (Y1068), AKT, pAKT, ERK, and pERK by a single-dose antibody or combined treatment with irinotecan in A431 xenograft tumor tissues.</div>

Journal of Immunology Research

fig4

Figure 4

Figure 4: A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan 